Since July, the internal trend of the US stock pharmaceutical industry has changed significantly. The share prices of Eli Lilly and Novo Nordisk, which have been rising and have high valuations, have fallen. Previously relatively lagging pharmaceutical stocks such as Bristol-Myers Squibb have soared and started to soar. Relevant analysis pointed out that the introduction of the Inflation Reduction Act (IRA) and the financial reports released by several large pharmaceutical companies including AbbVie and Bristol-Myers Squibb are the main reasons for the stock market rotation. So what are the pharmaceutical concept stocks worth paying attention to at present?

Merck (code: MRK)

Merck is a world-renowned pharmaceutical company headquartered in Kenilworth, New Jersey, USA. It is known for providing innovative medical solutions, including prescription drugs, vaccines, biologics and animal health products, serving more than 140 countries around the world.

Merck is committed to developing innovative drugs and is famous for developing vaccines. It specializes in tumors, diabetes, cardiovascular diseases and anti-infection. Merck's tumor immunotherapy drug Keytruda (pembrolizumab) has become a world-renowned anti-cancer drug, and its sales have exceeded Humira in 2023, becoming the world's new "king of drugs".

Merck will release its second-quarter financial report today. Previously, Merck's new drug Winrevair was approved, and today Merck will present the first batch of data on Winrevair sales to investors. The market is generally optimistic about Merck's new drug revenue. According to FactSet data, analysts expect the drug's sales to climb to US$6 billion in 2029, and are expected to reach US$57 million in the second quarter.

Source: uSMART SG

Biogen (code: BIIB)

Biogen, also known as Biogene, is a biopharmaceutical company engaged in the discovery, development and provision of treatment for neurological and neurodegenerative diseases. Its product line covers a variety of disease treatment areas, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS, commonly known as "Lou Gehrig's disease"), etc.

Biogen has made many remarkable achievements in the pharmaceutical field, successfully developing the world's first drug for the treatment of spinal muscular atrophy (SMA) - Spinraza, which has brought major breakthroughs in the field of rare diseases. In addition, Biogen has also made remarkable achievements in the treatment of multiple sclerosis (MS), such as Tecfidera and its upgraded version Vumerity.

In the past three months, 12 analysts have shared their evaluations of Biogen (NASDAQ: BIIB). When evaluating the 12-month price target, analysts proposed an average target of $311.58, a high estimate of $342.00, and a low estimate of $294.00. Currently, Biogen's stock price is $214.430.

Source: uSMART SG

Shuodi Bio (code: GPCR)

Shuodi Bio was founded on July 26, 2019. On February 3, 2023, Shuodi Bio was successfully listed on the Nasdaq in the United States. It is a young but successful biopharmaceutical company. At present, Shuodi has reached the clinical stage. Based on structure-based drug design technology, combined with advanced computing technology and world-class expertise, it is committed to transforming biologics and peptide drugs into oral small molecule drugs with excellent efficacy. It focuses on the development of G protein-coupled receptor (GPCR) targeted therapies, and 2 products in the pipeline have entered the clinical development stage.

At present, Shuodi Bio's stock price is US$39.55, far below the lowest price of US$65 estimated by analysts. The recent stock price performance has continued to hover at a low level, and has rebounded slightly in the past two days, with a trend of rising. Analysts' evaluations are all buy ratings.

Source: uSMART SG

How to trade on uSMART:

After logging into the uSMART SG APP, click "Search" from the top right of the page, enter the target code, such as "GPCR", to enter the details page to learn about the transaction details and historical trends, click "Trade" in the lower right corner, select the "Buy/Sell" function, and finally fill in the transaction conditions and submit the order; the picture operation instructions are as follows:

Source: uSMART SG

Follow us

Find us on Twitter, Instagram, YouTube, and TikTok for frequent updates on all things investing.

Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！

Important Notice and Disclaimer:

We have based this article on our internal research and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this article, we do not represent the information contained in this article is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this article. Opinions, projections and estimates reflect our assessments as of the article date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this article. Neither we or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this article.

This document should not be construed in any jurisdiction as constituting an offer, solicitation, recommendation, inducement, endorsement, opinion, or guarantee to purchase, sell, or trade any securities, financial products, or instruments or to engage in any investment or any transaction of any kind, nor is there any intention to solicit or invite the purchase or sale of any securities.

The value of these securities and the income from them may fall or rise. Your investment is subject to investment risk, including loss of income and capital invested. Past performance figures as well as any projection or forecast used in this article is not indicative of its future performance.

This advertisement has not been reviewed by the Monetary Authority of Singapore